Addition of rituximab to the CHOP regimen has no benefit in patients with primary extranodal diffuse large B-cell lymphoma

Korean Journal of Hematology

Volumn 46, Issue 2, 2011, Pages 103-110

  Jang, Geundoo ^a   Yoon, Dok Hyun ^a   Kim, Shin ^a   Lee, Dae Ho ^a   Lee, Sang Wook ^a   Huh, Jooryung ^b   Suh, Cheolwon ^a  

^a Hallym University Medical Center   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

Author keywords

CHOP; Diffuse large B cell lymphoma; Primary extranodal lymphoma; Rituximab

Indexed keywords

EID: 84859867323     PISSN: 17387949     EISSN: 20929129     Source Type: Journal    
DOI: 10.5045/kjh.2011.46.2.103     Document Type: Article

References (28)

1. Gatter KC, Warnke RA. Diffuse large B-cell lymphoma. In: Jaffe ES, Harris NL, Stein H, et al, eds. World Health Organization Classification of Tumors: Pathology and genetics of tumours of haematopoietic and lymphoid tissues. 3rd ed. Lyon, France: IARC Press, 2001:171-4.
2. Coiffier B. Diffuse large cell lymphoma. Curr Opin Oncol 2001; 13:325-34.
3. Gordon LI, Harrington D, Andersen J, et al. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. N Engl J Med 1992;327:1342-9.
4. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;328: 1002-6.
5. Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998;92:1927-32.
6. Vose JM, Link BK, Grossbard ML, et al. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol 2001;19:389-97.
7. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-42.
8. Feugier P, VanF Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. J Clin Oncol 2005;23:4117-26.
9. Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005;23:5027-33.
10. Pfreundschuh M, Trümper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7:379-91.
11. A predictive model for aggressive non-Hodgkin's lymphoma. The Iinternational Non-Hodgkin's Llymphoma prognostic factors project. N Engl J Med 1993;329:987-94.
12. Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor ofr outcome than the standard IPI for patients with diffuse large B-cell lymphoma DLBCL treated with R-CHOP. Blood 2007;109:1857-61.
13. Mounier N, Briere J, Gisselbrecht C, et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 2003;101:4279-84.
14. Winter JN, Weller EA, Horning SJ, et al. Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood 2006;107:4207-13.
15. Zucca E, Roggero E, Bertoni F, Cavalli F. Primary extranodal non-Hodgkin's lymphomas. Part 1: Gastrointestinal, cutaneous and genitourinary lymphomas. Ann Oncol 1997;8:727-37.
16. Newton R, Ferlay J, Beral V, et al. The epidemiology of non-Hodgkin's lymphoma: cComparison of nodal and extra- nodal sites. Int J Cancer 1997;72:923-30.
17. Otter R, Gerrits WB, vd Sandt MM, Hermans J, Willemze R. Primary extranodal and nodal non-Hodgkin's lymphoma. A survey of a population-based registry. Eur J Cancer Clin Oncol 1989;25:1203-10.
18. Shih LY, Liang DC. Non-Hodgkin's lymphomas in Asia. Hematol Oncol Clin North Am 1991;5:983-1001.
19. Aozasa K, Tsujimoto M, Sakurai M, et al. Non-Hodgkin's lymphomas in Osaka, Japan. Eur J Cancer Clin Oncol 1985;21:487-92.
20. Kim CW, Kim I, Ko YH, et al. Clinicopathologic and immunophenotypic study of non-Hodgkin's lymphoma in Korea. Lymphoreticular Study Group of the Korean Society of Pathologists. J Korean Med Sci 1992;7:193-8.
21. Kramer MH, Hermans J, Parker J, et al. Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: a population-based study. J Clin Oncol 1996;14:2131-8.
22. Houldsworth J, Mathew S, Rao PH, et al. REL proto-oncogene is frequently amplified in extranodal diffuse large cell lymphoma. Blood 1996;87:25-9.
23. Grønbaek K, Straten PT, Ralfkiaer E, et al. Somatic Fas mutations in non-Hodgkin's lymphoma: association with extranodal disease and autoimmunity. Blood 1998;92:3018-24.
24. Rao PH, Houldsworth J, Dyomina K, et al. Chromosomal and gene amplification in diffuse large B-cell lymphoma. Blood 1998;92: 234-40.
25. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-86.
26. Park YH, Lee JJ, Ryue MH, et al. Improved therapeutic outcomes of DLBCL after introduction of rituximab in Korean patients. Ann Hematol 2006;85:257-62.
27. Kramer MH, Hermans J, Parker J, et al. Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: a population-based study. J Clin Oncol 1996;14:2131-8.
28. Lopez-Guillermo A, Colomo L, Jimenez M, et al. Diffuse large Bcell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin. J Clin Oncol 2005;23:2797-804.